MARKET WIREYahoo Finance • 1d ago
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026Yahoo Finance report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
Why ELUT Stock slipped -1.92% Today — RQD Quant Desk Flash
$0.82 -1.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.82
Elutia Inc. (Class A) (ELUT) receives a Roarable Rating of E (Strong Sell) and flashes a Red SELL / AVOID rating (31/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+296.7% (NI vs OCF)).
ROARABLE E • RED ALERT
Cap $37.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ELUT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.82 (-1.92% 1D, market cap $37.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ELUT compare to PTHS and EXOZ in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, PTHS (Pelthos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and EXOZ (eXoZymes Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.4M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ELUT?
▼
Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.82 (-0.54%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY ELUT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.77+5.2% Next Q
23
Q2 (-2Q)Grade E$0.81+0% Next Q
26
Q3 (-1Q)Grade E$0.81+1.2% Next Q
28
CurrentGrade E$0.82-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze
While ELUT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.86) forces dealer call-delta covering toward $1.45.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ELUT Stock slipped -1.92% Today — RQD Quant Desk Flash
Elutia Inc. (Class A) (ELUT) slipped -1.92% to $0.82, trading at 36% of its 52-week range ($0.5 – $1.38). Weak 31/100 RQD score compounded by SEC accrual divergence (+296.7% (NI vs OCF)).
- ▸Technical Tape: Trading at 36% of its 52-week range ($0.5 – $1.38) with RSI-14 at 53.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.82 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: ELUT Accounting Gap: Net Income (+198.9%) Outpaced OCF (-97.8%) With +65.6% Working-Capital Build
Live ELUT Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Elutia, Inc. Estimates – BOATS:ELUTTradingView report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Elutia Inc. (ELUT) Seasonal returns chartYahoo Finance UK report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 33d ago
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan fa
RISK WATCHYahoo Finance • 54d ago
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15thGAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
MARKET WIREYahoo Finance • 62d ago
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment ConferenceGAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
CATALYSTYahoo Finance • 75d ago
Elutia (ELUT) Q2 2026 Earnings Call TranscriptCEO Mills reports 96% surgeon interest in NXT-41x platform ahead of late 2026 FDA clearance.
MARKET WIREYahoo Finance • 77d ago
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial LaunchDeal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the develop
MARKET WIREYahoo Finance • 81d ago
Elutia Inc. Q2 2026 Earnings Call SummaryMoby summary of Elutia Inc.'s Q2 2026 earnings call
CATALYSTYahoo Finance • 81d ago
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...Elutia Inc (ELUT) reports Q2 2026 results, highlighting robust surgeon interest in NXT41X and a strengthened balance sheet despite a slight revenue dip.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)
- ✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.81%⚡ TESTING RESISTANCE
2026-11-03O $0.82H $0.84L $0.82C $0.82VOL 138.3K
RES: $0.87SUP: $0.61SMA50: $0.83SMA200: $0.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -15.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)
Health Care Rank #771 of 1015
⚔️ PTHS vs ELUT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ELUT vs. PTHS, EXOZ, INMB, CRBU)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #771 by composite RQD confidence (31/100, grade E) and #776 by equity capitalization ($37.1M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. EXOZ currently holds the highest overall quantitative score in the immediate peer group at 32/100 (E) compared with ELUT at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELUT
ACTIVE
Elutia Inc. (Class A) | E | 31/100 | — | 53.7% | -35.0% | -1.92% | $37.1M | Benchmark Subject |
| PTHS Pelthos Therapeutics Inc. | E | 20/100 | — | 76.3% | -35.0% | +22.55% | $36.0M | /pths-vs-elut → |
| EXOZ eXoZymes Inc. | E | 32/100 | — | — | -35.0% | +9.44% | $38.4M | /exoz-vs-elut → |
| INMB INmune Bio Inc. | E | 30/100 | — | — | -35.0% | -4.83% | $44.9M | /inmb-vs-elut → |
| CRBU Caribou Biosciences Inc. | E | 32/100 | — | — | -35.0% | +3.95% | $45.4M | /crbu-vs-elut → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M , and -85.6% cumulative change since FY2023) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.3M | $53.4M | -$44.8M | -$46.7M | $62.4M | — |
| FY2024 (FY) | 2024-12-31 | $14.5M | -$53.9M | -$22.7M | -$23.3M | $36.1M | $22.6M |
| FY2023 (FY) | 2023-12-31 | $85.5M | -$37.7M | -$21.8M | -$21.8M | — | — |
3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.82 (-1.92% 1D, market cap $37.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
How does ELUT compare to PTHS and EXOZ in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, PTHS (Pelthos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and EXOZ (eXoZymes Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.4M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ELUT?
Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?
ELUT last traded at $0.82 (-1.92% on volume of 34,652 shares), positioning the stock -1.20% below its 50-day simple moving average ($0.83) and -15.46% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.38, ELUT sits at the 36.4% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.92).
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ SEC XBRL & RQD VERIFIED
ELUT — Elutia Inc. (Class A): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Elutia Inc. (Class A) (ELUT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.82 (-1.92% 1D, market capitalization $37.1M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 53.7%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (10/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Elutia Inc. (Class A) (ELUT) is a NASDAQ-listed issuer...0B, which conflicts with the $36.0M shown in market data; the profile figure is rounded to zero billions. — for product or customer detail.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported $12.3M in annual revenue (up from $14.5M in FY2024, -15.0% YoY) and $53.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($85.5M revenue, -$37.7M net income) through FY2025, ELUT scaled operating cash flow to -$44.8M and free cash flow to -$46.7M, backed by $62.4M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.50 – $1.38 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are therefore — The sector correlation is limited to Health Care / Biological Products. The primary 2nd-order risk the source identifies is the accrual gap: if working-capital build reverses, reported earnings could be pressured. Investors should watch the Q3 2026 release for cash realization against reported income.
- Key Question #1: Can ELUT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $12.3M and free cash flow of -$46.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ELUT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ELUT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Elutia Inc. (Class A) (ELUT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 Yahoo Finance report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Elutia, Inc. Estimates – BOATS:ELUT TradingView report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Elutia Inc. (ELUT) Seasonal returns chart Yahoo Finance UK report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 33d ago
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan fa
🔴 RISK WATCH Yahoo Finance • 54d ago
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
🟡 MARKET WIRE Yahoo Finance • 62d ago
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
🟢 CATALYST Yahoo Finance • 75d ago
Elutia (ELUT) Q2 2026 Earnings Call Transcript CEO Mills reports 96% surgeon interest in NXT-41x platform ahead of late 2026 FDA clearance.
🟡 MARKET WIRE Yahoo Finance • 77d ago
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the develop
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ELUT Bull vs. Bear Conversation Board — What's Your Call at $0.82?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELUT 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $0.99 (+17.9%)
📌 Pinned Debate FY 2025 reported net income of $53.4M, well above its -$26.9M operating income, and the stock trades at a $36.0M market cap against $36
Here is why I am bullish on ELUT here at $0.84: FY 2025 reported net income of $53.4M, well above its -$26.9M operating income, and the stock trades at a $36.0M market cap against $36.4M in cash.. Compare ELUT's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.80 are getting bought.
ArenaChamp_24 🐂 BULL
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (53.7%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $0.72 (-14.3%)
Spot @ $0.84 Operating income and free cash flow were negative in every reported period, the Butterfly Graph flags a 92-severity bearish accrual gap
Operating income and free cash flow were negative in every reported period, the Butterfly Graph flags a 92-severity bearish accrual gap, and the Altman Z-Score is 0.2.. Look at the math on ELUT: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.74 before getting long.